Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PFH + cyclosporine vs hydroxysaponin + cyclosporine for chronic ocular GVHD-related dry eye
ChiCTR2600116014Phase 4Not yet recruiting
- Sponsor
- Guangzhou First People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of cyclosporine in graft-versus-host disease (GVHD) (2 arms), sponsored by Guangzhou First People's Hospital. Primary endpoint: Ocular Surface Disease Index (OSDI) score. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
cyclosporine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2600116014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116014.